Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
Epilepsy, Partial
About this trial
This is an interventional treatment trial for Epilepsy, Partial focused on measuring Epilepsy, partial, Keppra, Levetiracetam
Eligibility Criteria
Inclusion Criteria: Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059 Patients/the parent or guardian wish to continue treatment with L059 and to enter N165 Follow-up Study, and also the investigator admit the necessity of the repeated intake of the investigational drug for the patients. Exclusion Criteria: Patients who had not participate in N165 Clinical Trial of L059. Patients who had participated in N165 Clinical Trial of L059 with no intention of entering the follow-up study taking the same medication. Patients had not been in compliance with requirements of Protocol for N165 Clinical Trial of L059 in the course of the study.
Sites / Locations
Arms of the Study
Arm 1
Experimental
Levetiracetam
Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).